Swiss drugmaker Roche is moving its experimental antibiotic zosurabalpin into the final phase of human testing against a common superbug bacteria. The antibiotic, jointly developed with Harvard University, will be tested against acinetobacter baumannii, which causes serious hospital infections like pneumonia and sepsis. Acinetobacter resistant to many existing antibiotics is a global issue, disproportionately affecting hospitalized patients. Roche’s new approach targets the bacteria without allowing it to develop resistance. The company hopes to bring this effective treatment to those in need soon.
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/roche-moves-antibiotic-against-superbug-into-phase-3-testing-2025-05-26